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It has been suggested that elevated leptin levels underlie the
low grade proinflammatory state in human obesity. We rea-
soned that if elevated leptin levels are an important factor in
the proinflammatory state in obesity, then exogenous leptin
administration during weight loss should counteract the con-
current beneficial effects of weight loss on the proinflamma-
tory state. We therefore determined whether long-acting
pegylated recombinant leptin (PEG-OB) prevents the de-
crease in cellular and humoral inflammation parameters dur-
ing a very low calorie diet in healthy overweight young men.
Except for B cells, PEG-OB treatment did not influence the
decline in total leukocyte count and mononuclear subfrac-
tions during the diet. Weight loss decreased the humoral in-
flammation parameters TNF, tissue plasminogen activator,
and von Willebrand factor (P < 0.05), but in combination with
PEG-OB treatment, a significant decrease was shown for in-
flammation markers as a whole (P < 0.014) and that of the
individual parameters tissue plasminogen activator, von Wil-
lebrand factor, plasminogen activator inhibitor type 1, and
intercellular adhesion molecule-1 (P < 0.05). The increase in
C-reactive protein levels (P < 0.05) was the sole indication for
a humoral proinflammatory action of leptin. Although
PEG-OB treatment significantly increased weight loss (P <
0.03), the data do not support a proinflammatory role of leptin
in human obesity. (J Clin Endocrinol Metab 89: 1773–1778,
2004)
HUMAN OBESITY IS associated with a chronic, lowgrade, proinflammatory state as indicated by leuko-
cytosis (1), increased plasma levels of the proinflammatory
cytokines IL-6 (2) and TNF, (3) elevated acute phase pro-
teins (4, 5), and increased levels of markers of endothelial cell
dysfunction and activation (6). Weight loss attenuates this
proinflammatory state (7).
Leptin is an adipocyte-derived polypeptide hormone that
controls body weight through central regulation of food in-
take and energy expenditure (8). Abundance of leptin mRNA
in adipose tissue and concentrations of leptin in the circu-
lation are strongly positively correlated with body weight
and adiposity in man; and human obesity is characterized by
elevated circulating leptin levels (9). Both leptin and its re-
ceptor share structural and functional similarities with the
IL-6 family of cytokines (10), and leptin appears to play a
critical role in the inflammatory response. Defective immune
responses are present in both leptin-deficient mice (11, 12)
and infants (13) as well as during starvation and malnutri-
tion, two conditions characterized by low levels of circulating
leptin (12). CD 34 hemopoietic stem cells (14) and most
leukocytes express the leptin receptor (15), and the stimu-
lating effects of leptin on leukocyte proliferation has been
well established in vitro (10). Further evidence from in vitro
and animal studies suggests that leptin is also involved in
regulation of the humoral inflammatory response through its
direct effects on T cells (10), monocytes (10, 16), neutrophils
(17), and endothelial cells (18, 19).
Weight loss reduces circulating leptin levels (20) and con-
comitantly lowers the plasma levels of inflammation markers
associated with obesity (7). The question thus arises whether
raised leptin levels underlie the proinflammatory state in
human obesity (21). In this paper we sought evidence for a
proinflammatory role of leptin in obesity through maintain-
ing elevated plasma leptin levels during weight loss. To that
end, moderately obese men were subjected to profound
weight loss induced by a very low calorie diet (VLCD) and
either received weekly injections of long-acting pegylated
human recombinant leptin (PEG-OB) (22, 23) or placebo. It
was reasoned that if elevated leptin levels are an important
factor in inducing an inflammatory state in obese humans,
exogenous leptin administration during weight loss would
counteract the concurrent beneficial effects on the proinflam-
matory state.
Subjects and Methods
Study population
The study was part of a larger study into the effects of PEG-OB
treatment on weight loss. Twenty-four overweight and moderately
obese Caucasian men (body mass index, 25–32 kg/m2) were recruited
through advertisements in local newspapers. All subjects had a stable
weight and were healthy according to medical history, clinical exami-
nation, and routine laboratory findings. To achieve balanced treatment
groups, patients were stratified and matched in pairs according to age,
body mass index, and plasma leptin and insulin concentrations. Ran-
Abbreviations: CRP, C-Reactive protein; HDL, high-density lipopro-
tein; ICAM, intracellular adhesion molecular; LDL, low-density lipopro-
tein; PAI-1, plasminogen activator inhibitor type 1; PEG-OB, pegylated
recombinant leptin; sTNFR, soluble TNF receptor; tPA, tissue plasmin-
ogen activator; VLCD, very low calorie diet; vWF, von Willebrand factor.
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domization numbers were generated and incorporated into the double-
blind labeling by an independent third party. Within the first week of
the study, two subjects in the placebo group dropped out voluntarily
because they were unable to sustain their diet; this did not influence
baseline characteristics of the study population. The study was ap-
proved by the medical ethical committee of University of Maastricht,
and all participants gave written informed consent.
Weight loss and treatment
Weight loss was induced through a very low calorie diet (2 MJ/d;
Modifast, Novartis, Breda, The Netherlands). The dietary prescription
was discussed weekly with a dietician, and compliance with the diet was
verified by measurement of weight loss. Body weight was measured on
a calibrated digital scale accurate to 0.1 kg.
During the study, patients either received weekly sc injections of 80
mg PEG-OB (10 mg/ml; produced and provided by Hoffmann-
La Roche, Inc., Nutley, NJ) or matching placebo (8 ml) in the para-
umbilical region. PEG-OB treatment was well tolerated. No indication
could be found for the occurrence of significant amounts of PEG-OB
neutralizing antibodies at the end of the study (d 46).
Blood sampling and biochemical analysis
Blood samples and plasma samples were obtained on d 1 (before the
start of the diet and PEG-OB treatment), 8, 15, 25, and 46 of the study.
Blood sampling was performed in the morning after at least an 8-h
overnight fast, immediately before study medication. Samples were
directly placed on melting ice and centrifuged within 1 h of sampling.
The extracted plasma was recentrifuged, frozen in liquid nitrogen, and
stored at 80 C until further analysis. All assays were performed in
duplicate.
Glucose was measured by the hexokinase method (Roche, Basel,
Switzerland), and insulin levels were measured at the certified central
laboratory of University Hospital Maastricht (Maastricht, The Nether-
lands). Estimated insulin sensitivity was assessed by homeostasis model
assessment (24): (fasting glucose  fasting insulin)/22.5.
Total cholesterol was measured by the CHOD-PAP method (Roche,
Mannheim, Germany), and the lipase method (Sigma-Aldrich Corp., St.
Louis, MO) was used to measure triglycerides. High density lipoprotein
(HDL) cholesterol was measured at the certified central laboratory of the
University Hospital Maastricht, The Netherlands. Low density lipopro-
tein (LDL) cholesterol was calculated with the Friedwald formula (25):
LDL cholesterol  total cholesterol  (0.45  triglycerides)  HDL
cholesterol.
Total leukocytes and mononuclear subpopulations were analyzed on
d 1 and 25 by fluorescence-activated cell sorting analysis. Plasma leptin
levels were measured by a double-antibody sandwich ELISA using a
monoclonal antibody specific for human leptin. This assay measures
both pegylated and free leptin (26). Plasma IL-1, IL-6, TNF, intercellular
adhesion molecular 1(ICAM-1), and tissue plasminogen activator
(tPA) were assessed by commercially available ELISA kits: PeliKane
compact kit (CLB, Amsterdam, The Netherlands) for IL-6, HS Quan-
tikine (R&D Systems, Abingdon, UK) for IL-1, TNF-1, and ICAM-1, and
Imulyse-1 (Biopool, Umea, Sweden) for tPA. C-Reactive protein (CRP),
vWF, and fibrinogen were measured by in-house ELISAs using com-
mercially available antibodies (DakoCytomation BV, Heverlee, Bel-
gium) as described previously (27–29). Details of the ELISAs for soluble
p55 and p75 TNF receptors (sTNFR55 and sTNFR75) have been de-
scribed previously (30). Plasminogen activator inhibitor type 1 (PAI-1)
antigen levels were assessed using a specific in-house sandwich ELISA
that measures latent, active, and complexed forms. The linearity of this
assay ranges from 2–30 ng/ml. The coefficients of variation for these
assays were less than 10%. The within- and between-day coefficients of
variation were 2.9% and 7.2% for CRP, 1.7% and 6.3% for fibrinogen, and
6% and 12% for PAI-1, respectively.
Statistics
Results are expressed as means (sd) or medians (range) where indi-
cated. Differences between start (d 1) and end of diet (d 46) values were
determined by paired t test or Wilcoxon rank-order test for paired
observations when applicable. For clarity, uncorrected P values are
provided in the text, but a Bonferroni correction should be considered
when interpreting the data.
The effects of weight loss on the proinflammatory state in the placebo
and PEG-OB groups were assessed by combining the individual proin-
flammatory parameters in a single model. To that end, plasma PAI-1,
IL-6, tPA, fibrinogen, and ICAM-1 values on d 1,8,15,25, and46
were logarithmically transformed and incorporated into a single model,
and the effect was analyzed as a multivariate response by multivariate
analysis of covariation, with time as the independent variable.
Results
Baseline characteristics of the study population and the
effects of weight loss on metabolic parameters are shown in
Table 1. The VLCD resulted in a rapid and substantial weight
loss and a significant decline in serum leptin levels in the
placebo-treated group (P  0.0001). Compensating for the
fall in serum leptin levels by PEG-OB treatment resulted in
a total (i.e. pegylated and endogenous) leptin level of 3980
704 ng/ml. Weight loss was significantly higher in the
PEG-OB group than in the placebo group (14.6  2.7 vs.
11.7  2.9 kg, respectively; P  0.03). Baseline leptin serum
concentrations immediately before leptin injection ranged
TABLE 1. Metabolic characteristics of placebo- and PEG-OB-treated groups before and after weight loss
Placebo (n  10) PEG-OB (n  12)
Before weight loss
(d 0)
After weight loss
(d 46)
Before weight loss
(d 0)
After weight loss
(d 46)
Age (yr) 36.4 (2.8) 34.6 (4.2)
Weight (kg) 96.6 (11.8) 84.8 (12.7)a 97.9 (6.6) 83.3 (5.6)a
Weight loss (kg) 11.8 (2.9) 14.6 (2.7)b
BMI (kg/m2) 28.8 (1.8) 25.4 (2.3)a 28.9 (1.3) 24.8 (1.5)a
Leptin (ng/ml) 7.10 (2.37) 2.01 (0.75)c 7.61 (4.22) 3980 (704)c
Glucose (mmol/liter) 5.2 (0.2) 4.7 (0.5)a 5.3 (0.3) 4.7 (0.3)c
Insulin (mU/liter) 9.4 (3.2) 3.6 (2.2)c 7.2 (2.8) 2.0 (1.0)c
HOMA 2.2 (0.8) 0.8 (0.5)c 1.7 (0.6) 0.4 (0.2)c
Cholesterol (mmol/liter) 4.8 (0.9) 3.7 (0.5)a 4.7 (0.8) 3.2 (0.5)a
LDL cholesterol (mmol/liter) 3.2 (0.8) 2.4 (0.3)a 2.8 (0.5) 1.8 (0.3)c
HDL cholesterol (mmol/liter) 1.1 (0.1) 1.1 (0.3) 1.2 (0.3) 1.1 (0.2)
Triacylglycerol (mmol/liter) 1.15 (0.60) 0.58 (0.22)a 1.13 (0.91) 0.48 (0.21)a
Values are given as means (SD). BMI, Body mass index.
a P  0.05.
b Significant difference between placebo and PEG-OB-treated group, P  0.03.
c P  0.001.
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from 950-3700 ng/ml. Peak concentrations, measured 72 h
after sc PEG-OB injection, ranged from 2300–6050 ng/ml.
Weight loss led to a significant decrease in fasting glucose
levels (P  0.03 and P  0.0001 in the placebo and PEG-OB
groups, respectively) and fasting insulin levels (P  0.001
and P  0.0001 in the control and PEG-OB groups, respec-
tively), resulting in an improved estimated insulin sensitivity
in both the placebo group (P  0.03) and the PEG-OB group
(P  0.001).
Total plasma cholesterol, LDL cholesterol, and triglycer-
ides were significantly lower after weight loss (P  0.02 in
both study groups). HDL cholesterol was not significantly
influenced by the VLCD.
The effects of the VLCD and PEG-OB treatment on the
cellular and humoral components of the immune system
have been summarized in Tables 2 and 3. In general, these
parameters show a gradual decline over the 46-d study pe-
riod, indicating that the fall in proinflammatory parameters
is not simply related to the VLCD (see also Fig. 1.)
Table 2 shows the effects of VLCD and PEG-OB treatment
on circulating cellular components of the immune system at
the end of the 46-d study period. Weight loss significantly
lowered total leukocyte count in both the placebo and
PEG-OB groups (P  0.01 and P  0.001, respectively). The
fall in total leukocytes was, with one exception, evenly dis-
tributed over the various mononuclear subfractions. Mono-
cytes, CD4, CD8, and NK cells decreased proportionally;
only CD19 cells (B lymphocytes) showed a small, but sig-
nificant (P  0.04), increase in the PEG-OB group.
Data on the evaluation of humoral inflammatory markers
are shown in Table 3. Of the parameters tested, only the
vascular endothelial cell activation markers tPA (P  0.004)
and vWF (P 0.03) and the proinflammatory cytokine TNF
(P  0.04) significantly decreased upon weight loss. Com-
pared with baseline values, no significant change was found
for IL-1, IL-6, sTNFR-55, sTNFR-75, CRP, fibrinogen, PAI-1,
or ICAM-1. Overall assessment of humoral inflammatory
markers in a model incorporating all relevant inflammatory
parameters showed a tendency to decline upon weight loss
(P  0.09).
The VLCD in combination with PEG-OB treatment re-
sulted in significant changes in the endothelial activation
markers tPA (P 0.001), vWF (P 0.002), and ICAM-1 (P
0.009) and in sTNFR-75 (P 0.044) and PAI-1 (P 0.002). No
significant changes in TNF, sTNFR-55, or fibrinogen were
observed. Overall assessment of all relevant parameters by
multivariate analysis of covariation revealed a gradual, sig-
nificant decline over time in the proinflammatory parameters
(P  0.014).
Although the VLCD generally induced a decrease in hu-
moral inflammatory markers, two exceptions were noticed
(Fig. 1). First, in the placebo group, but not in the PEG-OB
group, the VLCD induced a significant (P  0.02) 2-fold
increase in median IL-6 values on d 8, which had disappeared
TABLE 2. Effect of weight loss and PEG-OB-treatment on cellular inflammatory parameters
Placebo (n  10) PEG-OB (n  12)
Before weight loss
(d 0)
After weight loss
(d 46)
Before weight loss
(d 0)
After weight loss
(d 46)
Leucocytes (10E9/L) 7.7 (3.6) 4.7 (0.7)a 6.8 (1.7) 4.7 (1.3)b
Monocytes (%) 8.4 (2.9) 8.6 (1.8) 8.2 (1.1) 8.8 (3.0)
CD4 lymphocytes (%) 60.8 (10.9) 62.1 (8.2) 57.5 (7.8) 58.0 (6.9)
CD8 lymphocytes (%) 34.0 (8.3) 32.3 (7.7) 37.2 (6.1) 37.8 (5.8)
CD4/CD8 ratio 1.96 (0.96) 2.10 (0.90) 1.60 (0.47) 1.60 (0.45)
CD19 cells (%) 10.2 (4.4) 10.6 (3.6) 12.7 (3.0) 13.8 (3.1)a
NK cells (%) 12.2 (5.1) 7.8 (5.1) 14.8 (6.9) 11.1 (3.9)
Values are given as means (SD).
a P  0.05.
b P  0.001.
TABLE 3. Effect of weight loss and PEG-OB treatment on humoral inflammatory parameters
Placebo group (n  10) PEG-OB group (n  12)
Before weight loss
(d 0)
After weight loss
(d 46)
Before weight loss
(d 0)
After weight loss
(d 46)
IL-1 (ng/liter) ND ND ND ND
IL-6 (ng/liter) 1.32 [0.23–3.43] 0.62 [0.18–3.64] 1.20 [0.30–8.90] 0.74 [0.14–3.45]
TNF (ng/liter) 4.10 [1.96–5.30] 3.46 [1.46–4.74]a 3.04 [2.07–4.33] 2.72 [1.26–5.63]
sTNFR55 (g/liter) 0.33 (0.08) 0.31 (0.09) 0.30 (0.09) 0.28 (0.07)
sTNFR75 (g/liter) 1.08 (0.29) 1.08 (0.22) 1.35 (0.24) 1.15 (0.26)a
CRP (mg/liter) 2.75 [0.04–7.6] 0.93 [0.11–9.35] 1.30 [0.83–11.66] 2.66 [0.79–14.45]a
Fibrinogen (g/liter) 3.10 (1.11) 2.90 (0.93) 2.56 (0.77) 2.36 (0.52)
PAI-1 (g/liter) 20.7 (7.5) 13.5 (11.0) 21.5 (10.0) 6.9 (4.7)a
tPA (g/liter) 13.4 (10.6) 6.8 (7.1)a 11.9 (5.0) 4.03 (2.05)b
vWF (g/liter) 152.1 (39.6) 136.5 (38.0)a 160.8 (30.7) 136.1 (25.3)a
ICAM-1 (g/liter) 155.8 (13.2) 144.6 (23.9) 165.4 (34.1) 141.9 (31.4)a
Values are means (SD) or medians [range]. ND, Not detectable, below the detection limit of the assay (0.2 g/liter).
a P  0.05.
b P  0.001.
Hukshorn et al. • Leptin and the Proinflammatory State J Clin Endocrinol Metab, April 2004, 89(4):1773–1778 1775
 on March 4, 2005 jcem.endojournals.orgDownloaded from 
by d 15. Second, in the PEG-OB group, CRP levels peaked on
d 8 (P  0.004) and remained elevated for the remainder of
the study period.
Discussion
In addition to acting as a regulator of food intake and
energy expenditure, (8), there is a growing body of evidence
to suggest that leptin is a modulator of the immune and
proinflammatory responses (10, 12). Consequently, it has
been hypothesized that elevated leptin levels underlie the
low grade proinflammatory state associated with human
obesity (21). In the present study we found that high leptin
levels produced by PEG-OB treatment of overweight young
men during a VLCD significantly increased weight loss (31),
but our data do not support a proinflammatory role for leptin
in human obesity. With the exception of small increases in
CD19 cells and plasma CRP levels, PEG-OB treatment,
which compensated for the fall in serum leptin levels during
weight loss, did not counteract the changes in plasma levels
of cellular and humoral inflammatory markers during the
VLCD period. In fact, PEG-OB treatment further strength-
ened the beneficial effects of the diet on the inflammatory
state.
The additional weight loss in the PEG-OB group is in line
with studies in rodents, which also showed enhanced weight
loss upon leptin administration (8). The higher weight loss in
FIG. 1. Changes in the proinflamma-
tory parameters [total leukocytes
(mean), plasma IL-6 (median), CRP
(median), fibrinogen (mean), PAI-1
(median), tPA (mean), ICAM (mean),
and vWF (mean)] during weight loss in
the placebo group (F) and the PEG-OB
group (f).
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the PEG-OB-treated subjects appears primarily related to a
suppression of appetite during the VLCD. Voluntary weight
loss in man has been shown to be accompanied by an increase
in baseline appetite (32) and in the relevant human studies
reported to date a decrease in appetite, rather than an in-
crease in energy expenditure, was found to underlie the
enhanced weight loss in leptin-treated individuals (31,
33–35).
The current data on the beneficial effects of weight loss on
cellular and humoral markers of inflammation are in accor-
dance with other reports. Field et al. (36) also reported that
total leukocyte count and mononuclear subfractions decline
during weight loss induced by a VLCD in moderately obese
subjects. A beneficial effect of weight loss on circulating
levels of TNF in obesity has been shown by Dandona et al.
(3) and Zahorska et al. (37). Heilbronn et al. reported a decline
in plasma CRP levels in proportion to weight loss (38).
With the exception of a minor fractional enrichment in
CD19 lymphocytes and an increase in plasma CRP levels,
we found that PEG-OB treatment enhanced, rather than an-
tagonized, the beneficial effects of weight loss on proinflam-
matory markers. Our data are seemingly in contrast with
previous reports that showed a proinflammatory role for-
leptin. Fantuzzi et al. (10) extensively reviewed a putative
role of leptin in the modulation of the innate immune re-
sponse, inflammation, and hemopoiesis. Also, Yamagishi et
al. (18) and Bouloumie´ et al. (19) reported proinflammatory
effects of leptin on endothelial cell activation. Wang et al. (39)
and Dowidar et al. (40) showed direct effects of leptin on the
hepatocyte. The discrepancies between the present results
and those reported in the cited references are unlikely to be
related to the high leptin levels in our study, because
Zarkesh-Esfahani et al. (16) also used high leptin concentra-
tions in their leukocyte studies. Also, the apparent efficacy of
PEG-OB is less than that of native leptin (Campfield, L. A.,
unpublished observations), resulting in lower effective leptin
concentrations. The discrepancies may be related, however,
to in vitro/in vivo differences, species differences, (13), as well
as differences in model systems. For example, several reports
indicate that exogenous leptin induces a profound suppres-
sion of appetite in rodents (8), whereas exogenous leptin
administration in humans induces only a very modest sup-
pression of appetite (31, 33–35). Moreover, most data on the
proinflammatory role of leptin were obtained in leptin-
deficient animals and/or situations such as starvation, which
are characterized by low circulating leptin levels (12). Ap-
parently these findings cannot simply be extrapolated to the
human situation, in which obesity is characterized by ele-
vated plasma leptin levels and diminished leptin respon-
siveness (41).
The increase in plasma CRP levels in the PEG-OB-treated
group is the only significant proinflammatory effect of leptin.
CRP is a classical and highly sensitive acute phase protein,
plasma levels of which typically increase 100-fold or more
during inflammation. The 2-fold increase in CRP levels upon
PEG-OB treatment is indicative of only a weak inflammatory
response and may result from the direct interaction of leptin
and its receptor on hepatocytes, which interaction has been
reported to induce IL-6-type responses (12, 40, 41). CRP is a
strong predictor of cardiovascular risk, and indirect evidence
suggests that CRP may directly be involved in atheroscle-
rosis (42). No evidence for such a mechanism was found in
this study, and the decline in the endothelial cell activation
markers vWF and ICAM-1 was similar in both study groups.
An interesting finding is the increase in IL-6 concentration
on d 8 in the placebo-group, an increase that was absent in
the PEG-OB group. We are not aware of similar observations
during acute (semi) starvation. An increased plasma IL-6
concentration has been reported upon strenuous exercise,
and it was speculated that these elevated levels reflect a
muscle-derived signal, indicating critically low muscle gly-
cogen stores and signaling the liver to increase glucose out-
put (43). The observed increase in IL-6 upon initiation of the
very low calorie diet may serve similar purposes. The ap-
parent suppression of the IL-6 surge by PEG-OB concurs
with the proposed role of leptin as a peripheral signal, sig-
naling the brain to initiate adaptive responses to starvation
(44).
In conclusion, in this prospective study no evidence was
found for a causative role of leptin in the proinflammatory
state associated with human obesity. We found that high
leptin levels, produced by PEG-OB treatment, increased
weight loss in moderately obese men during a VLCD. The
apparent higher decline in inflammatory parameters in the
PEB-OB group may relate to the higher weight loss in this
group.
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